BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35676472)

  • 41. Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia.
    Zhai W; Sun Y; Jiang M; Wang M; Gasiewicz TA; Zheng J; Chang C
    Oncogene; 2016 Sep; 35(37):4866-80. PubMed ID: 26973243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.
    Gordan JD; Lal P; Dondeti VR; Letrero R; Parekh KN; Oquendo CE; Greenberg RA; Flaherty KT; Rathmell WK; Keith B; Simon MC; Nathanson KL
    Cancer Cell; 2008 Dec; 14(6):435-46. PubMed ID: 19061835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Correlation of cyclin D1 overexpression to mutations of von hippel-lindau gene in renal clear cell carcinoma].
    Ren YY; Du LJ; Feng ZQ; Leng J
    Ai Zheng; 2006 Feb; 25(2):175-8. PubMed ID: 16480581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined Deletion of Vhl and Kif3a Accelerates Renal Cyst Formation.
    Lehmann H; Vicari D; Wild PJ; Frew IJ
    J Am Soc Nephrol; 2015 Nov; 26(11):2778-88. PubMed ID: 25788526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
    Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
    Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
    Gao W; Li W; Xiao T; Liu XS; Kaelin WG
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice.
    Albers J; Rajski M; Schönenberger D; Harlander S; Schraml P; von Teichman A; Georgiev S; Wild PJ; Moch H; Krek W; Frew IJ
    EMBO Mol Med; 2013 Jun; 5(6):949-64. PubMed ID: 23606570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Anal Cell Pathol (Amst); 2010; 33(3):121-32. PubMed ID: 20978319
    [TBL] [Abstract][Full Text] [Related]  

  • 49. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells.
    Wolf C; Smith S; van Wijk SJL
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408930
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The renal cancer risk allele at 14q24.2 activates a novel hypoxia-inducible transcription factor-binding enhancer of DPF3 expression.
    Protze J; Naas S; Krüger R; Stöhr C; Kraus A; Grampp S; Wiesener M; Schiffer M; Hartmann A; Wullich B; Schödel J
    J Biol Chem; 2022 Mar; 298(3):101699. PubMed ID: 35148991
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
    Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
    Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis.
    Pasupuleti V; Du W; Gupta Y; Yeh IJ; Montano M; Magi-Galuzzi C; Welford SM
    J Biol Chem; 2014 Feb; 289(6):3713-23. PubMed ID: 24356968
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth.
    Vindrieux D; Devailly G; Augert A; Le Calvé B; Ferrand M; Pigny P; Payen L; Lambeau G; Perrais M; Aubert S; Simonnet H; Dante R; Bernard D
    Oncotarget; 2014 Feb; 5(4):1004-13. PubMed ID: 24657971
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth.
    Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X
    Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
    Sudarshan S; Shanmugasundaram K; Naylor SL; Lin S; Livi CB; O'Neill CF; Parekh DJ; Yeh IT; Sun LZ; Block K
    PLoS One; 2011; 6(6):e21037. PubMed ID: 21695080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
    Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
    Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: A helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system.
    Carney EM; Banerjee P; Ellis CL; Albadine R; Sharma R; Chaux AM; Burger PC; Netto GJ
    Am J Surg Pathol; 2011 Feb; 35(2):262-7. PubMed ID: 21263247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.